RESEARCH BOARD / ABOUT
About Legal Sermorelin
An independent editorial project that summarizes the peer-reviewed research on sermorelin — organized, cited, and bounded by the evidence.
What this site is
Legal Sermorelin is an independent editorial project that publishes summaries of the peer-reviewed research literature on sermorelin. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science — the GHRH(1-29) record laid out cell by cell, with every quantitative claim cited to its study.
The structure is deliberate. The sermorelin literature is not one running story; it is a set of distinct, self-contained facts — a pediatric efficacy result, an aging GH/IGF-1 reversal, a pharmacokinetic profile, a body-composition signal that lives in a related analog, a regulatory history. We present each on its own terms, sized by how much weight the evidence actually carries, so a reader can see at a glance which findings are load-bearing and which are context.
What "legal" means here
The word "legal" in the domain is editorial framing — a position this publisher occupies relative to the regulatory record, not a claim about services we offer or a legal opinion. We summarize what the documented status of sermorelin actually is: it was an FDA-approved prescription drug for idiopathic growth hormone deficiency / short stature in children, withdrawn from the US market in 2008 for commercial reasons (not safety or efficacy), and is now prepared by compounding pharmacies, treated as a Category 1 bulk drug substance under FDA's interim Section 503A policy (final guidance January 2025). It is not a controlled substance. Growth-hormone secretagogues, including GHRH analogs, are prohibited in sport by WADA. We state these facts; we do not give legal advice.
What is sermorelin used for?
Its one historical FDA-approved use was evaluating and treating idiopathic growth hormone deficiency / short stature in children [1]. It has since been studied in research settings for the aging GH/IGF-1 decline, cognition, and body composition [2][6], and its drug class (GHRH analogs, including the stabilized analog tesamorelin) has been studied in HIV-associated lipodystrophy [11]. We describe these uses as research and regulatory history, not as recommendations.
How we handle the evidence
We lead with what was measured and attribute it to source. Where the body-composition evidence belongs to tesamorelin rather than GHRH(1-29), we say so rather than letting the family resemblance blur the claim. Where data are absent — long-term adult safety, demonstrated stand-alone weight loss — we mark the gap instead of filling it. An Annals of Internal Medicine editorial's caution that GH-secretagogue anti-aging use is "not yet ready for prime time" sits on this board beside the positive findings, not behind them [5].